ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Feb 05, 2020 19:40 JST
Source:
Jacobson Pharma Corporation Limited
Jacobson Pharma Launches First Influenza/RSV Home Diagnostic Kit in Hong Kong and Macau
HONG KONG, Feb 05, 2020 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Group"; Stock Code: 2633), a leading company engaged in research, development, production, marketing and sale of generic drugs and branded healthcare products, announced the launch of its first home diagnostic product for influenza/RSV under the brand name of "Dr. Freeman Flu/RSV Combo" (the "Product") in Hong Kong and Macau since January 2020. The product is available in different over-the-counter channels including major healthcare chain stores and drug stores.
Jacobson launches Dr. Freeman Flu/RSV Combo as its first influenza/RSV home diagnostic kit in the markets of Hong Kong and Macau. It is designed for qualitative determination of specific types of Influenza A and B virus and respiratory syncytial virus ("RSV") with test results available in 8 minutes.
Dr. Freeman Flu/RSV Combo is a handy one-step home diagnostic test designed for qualitative determination of specific types of Influenza A and B virus and respiratory syncytial virus ("RSV") with test results available in 8 minutes. The Product marks the first among others of its home diagnostic portfolio to be launched under the branded healthcare business platform of the Group. The Group is contemplating a potential strategic spin-off of its branded healthcare business which comprises proprietary medicines, proprietary Chinese medicines and branded health and wellness products such as health supplements, personal care products and diagnostic kits.
In scientific terms, Dr. Freeman Flu/RSV Combo uses monoclonal antibodies specific to the corresponding antigens of influenza and RSV for determination of the specific types of influenza and RSV infected, apart from the indication of the presence of influenza.
Mr Derek Sum, Chairman and Chief Executive Officer of Jacobson Pharma, commented, "We are very pleased for bringing in this useful home diagnostic product for influenza /RSV to the markets in Hong Kong and Macau. As a handy, speedy and specific self-diagnostic tool for the communicable disease, we believe the Product can highly benefit the public by helping influenza/RSV infected patients to seek prompt and effective medical treatment at the onset of the illnesses, especially during the peak flu seasons.
Bearing with the commitment to fulfilling unmet healthcare needs of consumers, we will continue to enhance our portfolio with high quality, innovative and well-trusted products in the expansion of our branded healthcare business as a strategic growth platform. Our ongoing efforts are set to strengthen our long-term strategic position and thereby enhancing the shareholders' values.".
About Jacobson Pharma Corporation Limited (Stock Code: 2633)
Jacobson Pharma is a leading generic drug company in Hong Kong. The Group's proprietary brand portfolio, notably being Po Chai Pills, Ho Chai Kung Tji Thung San, Contractubex Scar Gel, Flying Eagle Wood Lok Medicated Oil, Tong Tai Chung Woodlok Oil, Doan's Ointment, Saplingtan, Shiling Oil and Col-gan Tablet have been widely recognised by the market. The Group aims at the continued strategic enrichment of both of its generic drug and branded healthcare portfolios through the addition of high value-added products. With its corporate headquarters based in Hong Kong, the Group has also established its operating subsidiaries in China, Macau, Taiwan, Singapore and Cambodia forming a regional commercial platform to tap the market potential in the Asia Pacific and Greater China region. Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017. For more details about Jacobson Pharma, please visit the Group's website:
http://www.jacobsonpharma.com
For media enquiries, please contact:
Strategic Financial Relations Limited
Vicky Lee Tel: (852) 2864 4834 Email:
vicky.lee@sprg.com.hk
Stephanie Liu Tel: (852) 2864 4852 Email:
stephanie.liu@sprg.com.hk
Rachel Ko Tel: (852) 2864 4806 Email:
rachel.ko@sprg.com.hk
Fax: (852) 2527 1196
Source: Jacobson Pharma Corporation Limited
Sectors: Daily Finance, Daily News, Healthcare & Pharm
Copyright ©2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
NEC Strengthens Multi-Vendor Optical Network Solutions with New TIP-Certified Phoenix Hardware Lineup
Feb 27, 2026 18:50 JST
NEC Demonstrates Agentic AI-Driven Autonomous Network Operations in Collaboration with AWS
Feb 27, 2026 17:31 JST
Mitsubishi Heavy Industries Compressor Acquires Swiss Rotating Equipment Maintenance Company AST Turbo AG
Feb 27, 2026 17:23 JST
NEC Strengthens Its Edge Portfolio for the 6G Era, Enabling Efficient Edge Deployment and Integration with Cloud Services
Feb 27, 2026 12:24 JST
Fujitsu POS solution enhances customer experience at Hankyu Hanshin Department Stores
Feb 27, 2026 12:03 JST
Mitomo Semicon Engineering to Change Company Name
Feb 26, 2026 22:00 JST
The University of Tokyo, NTT, and NEC demonstrate real-time augmented reality assistance made possible by integrating three newly proposed technologies on a 6G/IOWN platform to realize the widespread use of AI agents supporting safety and security
Feb 26, 2026 19:01 JST
NEC and Nokia to Expand Eletronet's Optical Fiber Network in Brazil by 50%
Feb 26, 2026 18:51 JST
Everest Medicines Shareholders Pass Resolutions Including Commercialization Service Agreement at EGM
Feb 25, 2026 21:59 JST
Toyota Launches New bZ4X Touring BEV Focused on Driving Performance and Spaciousness in Japan
Feb 25, 2026 21:58 JST
DOCOMO and Keio University Demonstrate World's First Stable, High-Fidelity Robot Teleoperation via Commercial 5G Using Low-Latency Slicing
Feb 25, 2026 21:01 JST
DOCOMO Successfully Demonstrates AI Application Operation Using Virtualized Radio Access Network (vRAN) Infrastructure
Feb 25, 2026 20:50 JST
DOCOMO Begins Commercial Deployment of Agentic AI System for Network Maintenance Using One of the World's Largest Datasets
Feb 25, 2026 20:40 JST
NEC Implements AI Code Review Service "Metabob," Reducing Technical Verification Time by Up to 66%
Feb 25, 2026 18:00 JST
Beisia Automates Supermarket Refrigerator Temperature Monitoring and Recording with Fujitsu's IoT Visualization Solution
Feb 25, 2026 12:00 JST
Hong Kong Tech Delegation Heading for Market Expansion at Mobile World Congress 2026
Feb 25, 2026 07:00 JST
TANAKA to Provide Medals for the Tokyo Marathon 2026 That Represent All the Participants in the Event with Woven Lines
Feb 24, 2026 22:00 JST
Mitsubishi Shipbuilding Ships First Units of Systems for Marine Ammonia-Fueled Engines
Feb 24, 2026 20:07 JST
MHI Unveils "DIAVAULT," a Secure, High Performance Edge Data Center Platform
Feb 24, 2026 19:55 JST
Galaxy Payroll Group Renews Five-Year Strategic Cooperation Agreement with NIKE China Holding HK Limited (Macau Branch)
Feb 24, 2026 13:35 JST
More Latest Release >>
Related Release
Jacobson Pharma Announces FY2025 Interim Results
November 22 2024 10:00 JST
Jacobson Pharma Announces FY2023 Interim Results
November 25 2022 21:21 JST
Jacobson Pharma Announces FY2022 Annual Results
June 29 2022 23:20 JST
Ban Loong, Jacobson & JBM Form Joint Venture to Tap Specialty Drugs and Branded Healthcare Markets in Greater China and Asia
June 15 2022 19:56 JST
Jacobson Pharma's Chairman Uplifts Shareholding to Above 60%
March 14 2022 19:58 JST
Jacobson Pharma Announces FY2022 Interim Results
November 26 2021 19:39 JST
Jacobson Pharma Announces FY2021 Annual Results
June 29 2021 23:19 JST
JBM (Healthcare) Limited Debuts on The Main Board of SEHK
February 05 2021 16:28 JST
JBM (Healthcare) Limited to Be Spun Off from Jacobson Pharma Corporation Limited
January 25 2021 17:20 JST
Jacobson Pharma's Proposed Spin-off and Separate Listing of JBM (Healthcare) Limited on The Main Board of The Stock Exchange of Hong Kong Limited
January 15 2021 23:25 JST
More Press release >>